Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743509 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00743509 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 49 participants.
The verdict
NCT00743509, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or conventional chemotherapy.
Interventions
- DRUG Cyclophosphamide and Sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743509
The ClinicalTrials.gov registry entry for NCT00743509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclophosphamide and Sirolimus is the first listed.
NCT00743509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743509 about?
NCT00743509 is a clinical study titled "A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma". The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or conventional chemotherapy.
What is the current status of trial NCT00743509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2008-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00743509?
The interventions under investigation include: Cyclophosphamide and Sirolimus (DRUG).
Who is sponsoring clinical trial NCT00743509?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.